Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 740 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Infections, Acute Clear all
Completed Not applicable Interventional Results available

CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))

NCT04756141
View directory record Official record
Conditions
Diabetes Mellitus, Covid19
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

NCT01537081
View directory record Official record
Conditions
Acute Upper Respiratory Tract Infection
Interventions
Mucinex, Immediate-release Guaifenesin, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
12 Years and older
Enrollment
2,810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Hoover, Alabama • Bell Gardens, California • Harbor City, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 2, 2026, 2:29 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

NCT04583280
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Rilematovir, Rilematovir X mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Day to 5 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Orlando, Florida • Jackson, Mississippi • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

NCT04519437
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
REGN10933+REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 2, 2026, 2:29 AM EDT
Terminated Phase 4 Interventional Results available

Acute Cough Study In Children

NCT01257542
View directory record Official record
Conditions
Common Cold, Infections, Upper Respiratory Tract
Interventions
Dextromethorphan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Pinellas Park, Florida • Indianapolis, Indiana • Gresham, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

NCT04340557
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
Losartan
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 2, 2026, 2:29 AM EDT
Recruiting No phase listed Observational

The APS Phenotyping Study

NCT06521502
View directory record Official record
Conditions
ARDS, Sepsis, Pneumonia
Interventions
Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan
Other · Procedure · Radiation
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 2, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

NCT04958954
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Not applicable Interventional

Biosound Therapy as a Treatment for Long COVID Patients

NCT05848401
View directory record Official record
Conditions
Long COVID
Interventions
Biosound Therapy System
Device
Lead sponsor
Anxiety Relief Center
Other
Eligibility
20 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fishers, Indiana
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 2, 2026, 2:29 AM EDT
Completed No phase listed Observational

Stellate Ganglion Block to Treat Long COVID 19 Case Series

NCT05812209
View directory record Official record
Conditions
Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome, Dysautonomia, Anosmia, Dysgeusia, Brain Fog, Muscle Pain, Shortness of Breath, Dizziness, Fatigue Post Viral, Cough, Menstrual Cycle Abnormal, Pain
Interventions
Stellate Ganglion Block
Procedure
Lead sponsor
Metamorphosis LTD
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cañon City, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Not applicable Interventional

The COPE Study: Pilot Intervention to Improve Symptom Self-management and Coping in Adults With Post COVID-19

NCT05658536
View directory record Official record
Conditions
Post COVID-19 Condition, Post-COVID-19 Syndrome
Interventions
6-Week Self-Management Group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

NCT05472090
View directory record Official record
Conditions
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
Interventions
TNX-102 SL, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Oceanside, California • Santa Ana, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FluSAFE: Flu SMS Alerts to Freeze Exposure

NCT03274310
View directory record Official record
Conditions
Influenza, Acute Respiratory Infection, Influenza-like Illness
Interventions
Educational text messages
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
1,918 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Broad Implementation of Outpatient Stewardship

NCT05127161
View directory record Official record
Conditions
Acute Respiratory Tract Infection, Otitis Media, Pharyngitis, Acute Sinusitis
Interventions
Broad Implementation of Outpatient Stewardship (BIOS) intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 12 Years
Enrollment
1,032 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
5
States / cities
Plantation, Florida • Cleveland, Ohio • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 PrEP HCW HCQ Study

NCT04354870
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 2, 2026, 2:29 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

hCT-MSCs for COVID19 ARDS

NCT04399889
View directory record Official record
Conditions
COVID, Corona Virus Infection, COVID19
Interventions
Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

BAY12-8039: 5 Days for Sinusitis vs Placebo

NCT00492024
View directory record Official record
Conditions
Sinusitis
Interventions
Moxifloxacin (Avelox, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Northport, Alabama • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 2, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV

NCT04958889
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), HIV
Interventions
No intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 2, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

NCT05172024
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
15,172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Paxlovid for Treatment of Long Covid

NCT05576662
View directory record Official record
Conditions
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Interventions
Nirmatrelvir, Placebo, Ritonavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 2, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)

NCT02105298
View directory record Official record
Conditions
Respiratory Failure, Acute Respiratory Failure Requiring Reintubation, Pulmonary Edema, Pneumonia, Hypoxia, Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
104,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Echinacea and Acute Respiratory Illness

NCT02003651
View directory record Official record
Conditions
Acute Respiratory Infections
Interventions
Quick Defense, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

NCT03202394
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
BIO-11006, Placebo
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D for Sickle-cell Respiratory Complications

NCT01443728
View directory record Official record
Conditions
Sickle Cell Disease, Vitamin D Deficiency, Acute Chest Syndrome, Asthma, Respiratory Infections
Interventions
Experimental: Vitamin D3 100,000 IU, Active Comparator: Vitamin D3 12,000 IU
Drug
Lead sponsor
Gary M Brittenham, MD
Other
Eligibility
3 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 2, 2026, 2:29 AM EDT